Source comparison
Tesamorelin Comparison: VAT Reduction vs Other Approaches
Tesamorelin 2mg daily 15–20% Minimal (<1%) GHRH-mediated GH stimulation → selective HSL activation in visceral adipocytes Reverses within 12 weeks of stopping Most targeted pharmacological option for VAT. But requires ongoing treatment and offers no benefit fo
This comparison does not assign a generated winner or score.
- Tesamorelin 2mg daily
- 15–20%
- Minimal (<1%)
- GHRH-mediated GH stimulation → selective HSL activation in visceral adipocytes
- Reverses within 12 weeks of stopping
- Most targeted pharmacological option for VAT. But requires ongoing treatment and offers no benefit for subcutaneous fat
- Caloric deficit (500 kcal/day)
- 8–12%
- 12–18%
- Energy deficit → non-selective triglyceride mobilisation from all depots
- Weight regain common if deficit not sustained
- Reduces total fat mass but doesn't preferentially target VAT. Subcutaneous fat often mobilises first
- GLP-1 agonist (semaglutide 2.4mg weekly)
- 10–14%
- 14–20%
- Appetite suppression → caloric deficit + possible direct lipolytic effect
- Weight regain typical within 12 months of stopping
- Reduces total body fat but VAT reduction is secondary to overall weight loss. Not selective for visceral depots
- Growth hormone (rhGH 2–4 IU daily)
- 18–25%
- Direct GH receptor activation → global lipolysis with VAT preference
- Reverses within 8 weeks
- More potent than tesamorelin but carries higher risk of hyperglycaemia, oedema, and IGF-1 elevation. Typically reserved for GH-deficient patients
- Resistance training + protein 1.6g/kg
- 5–8%
- 3–6%
- Increased lean mass → elevated basal metabolic rate + improved insulin sensitivity
- Maintained only with continued training
- Slowest VAT reduction but improves muscle mass and metabolic health. Complementary to pharmacological approaches